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Abstract
Nuclear and mitochondrial genome mutations lead to various
mitochondrial diseases, many of which affect the mitochondrial
respiratory chain. The proteome of the intermembrane space (IMS)
of mitochondria consists of several important assembly factors
that participate in the biogenesis of mitochondrial respiratory
chain complexes. The present study comprehensively analyzed a
recently identified IMS protein cytochrome c oxidase assembly
factor 7 (COA7), or RESpiratory chain Assembly 1 (RESA1) factor
that is associated with a rare form of mitochondrial leukoen-
cephalopathy and complex IV deficiency. We found that COA7
requires the mitochondrial IMS import and assembly (MIA) path-
way for efficient accumulation in the IMS. We also found that
pathogenic mutant versions of COA7 are imported slower than the
wild-type protein, and mislocalized proteins are degraded in the
cytosol by the proteasome. Interestingly, proteasome inhibition
rescued both the mitochondrial localization of COA7 and complex
IV activity in patient-derived fibroblasts. We propose proteasome
inhibition as a novel therapeutic approach for a broad range of
mitochondrial pathologies associated with the decreased levels of
mitochondrial proteins.
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Introduction
The constant import of nuclear-encoded mitochondrial proteins into
mitochondria is required for healthy and functional mitochondria.
Mitochondrial precursor proteins utilize various versatile import
machineries for efficient import and proper localization into the
destined subcompartments, including the outer membrane (OM),
intermembrane space (IMS), inner membrane (IM), and matrix
(Neupert & Herrmann, 2007; Chacinska et al, 2009; Endo &
Yamano, 2010; Schmidt et al, 2010; Schulz et al, 2015; Wasilewski
et al, 2017). The mitochondrial intermembrane space import and
assembly (MIA) pathway is responsible for the import and stable
accumulation of cysteine-rich proteins in the IMS (Chacinska et al,
2004; Naoe et al, 2004; Terziyska et al, 2005). The MIA pathway
includes oxidoreductase MIA40/CHCHD4 (Mia40 in yeast), which
recognizes and oxidizes substrate proteins, and ALR/GFER (Erv1 in
yeast), which receives electrons from oxidation of a substrate (Hof-
mann et al, 2005; Mesecke et al, 2005; Muller et al, 2008; Banci
et al, 2009, 2010; Sztolsztener et al, 2013; Koch & Schmid, 2014;
Peleh et al, 2016). The classic MIA40 substrates are mostly small
proteins (< 20 kDa), such as TIMM8A and COX6B, with a specific
arrangement of cysteine residues, such as CX3C or CX9C (Koehler,
2004; Milenkovic et al, 2009; Sideris et al, 2009; Bourens et al,
2012; Fischer et al, 2013). MIA40 is also involved in the import of
non-canonical substrates, which do not possess CX3C or CX9C
signals in their sequence such as apurinic/apyrimidinic endonucle-
ase (APE1), cellular tumor antigen p53, and mitochondrial calcium
uptake 1 (MICU1) in metazoan and Tim22 in yeast (Wrobel et al,
2013; Zhuang et al, 2013; Barchiesi et al, 2015; Petrungaro et al,
2015).
Mitochondrial dysfunction is associated with many diseases
(Costa & Scorrano, 2012; Viscomi et al, 2015; Gorman et al, 2016;
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Suomalainen & Battersby, 2018). Among these, the impaired biogen-
esis of MIA40 and its substrates contributes to a significant percent-
age of mitochondrial pathology (Koehler et al, 1999; Tranebjaerg
et al, 2000; Roesch et al, 2002; Friederich et al, 2017; Erdogan et al,
2018). Interestingly, mutations of MIA40 substrates (e.g., TIMM8A,
COX6B, and NDUFB10) are associated with the significant loss of
proteins in patients, consequently leading to impairments of the
biogenesis of many other IMS and IM proteins.
Many mitochondrial precursor proteins, before they productively
reach the mitochondrial compartment, are under control of the
ubiquitin–proteasome system (UPS), a major protein-degrading
pathway that is involved in maintaining cellular protein homeosta-
sis (Radke et al, 2008; Bragoszewski et al, 2013). Furthermore, IMS
proteins can undergo reductive unfolding and slide back to the
cytosol where they are also degraded by the UPS (Bragoszewski
et al, 2015). However, the contribution of cytosolic protein control
mechanisms to mitochondriopathies has not been investigated.
The present study identified a cysteine-rich IMS protein, COA7,
as a new non-canonical substrate of MIA40. COA7 is a Sel1 repeat-
containing protein that was previously shown to be involved in the
assembly of respiratory chain complexes I and IV (Kozjak-Pavlovic
et al, 2014; Martinez Lyons et al, 2016). We characterized the inter-
action of COA7 with MIA40 and its import and localization in mito-
chondria. We also characterized pathogenic disease-causing COA7
mutants (Martinez Lyons et al, 2016) as defective in their biogenesis
and degraded in the cytosol by the UPS. Importantly, inhibition of
the UPS system led to the partial rescue of defective COA7 variants,
thus suggesting a conceptually novel strategy for therapeutic
interventions.
Results
COA7, new MIA40-interacting protein
To identify new interacting partners/substrates of MIA40, we
performed affinity purification of MIA40FLAG that was induced in
human Flp-In T-Rex 293 cells and subjected the eluate fraction to
mass spectrometry. Specificity was calculated as the ratio of the
protein signal intensity in the bait purification (MIA40FLAG) to the
protein signal intensity in the control purification. The identifi-
cation of previously known MIA40-interacting proteins (ALR and
AIF1) and MIA40 substrates (TIMM13 and COX6B) validated the
specificity of our affinity purification. Among the proteins that
co-purified with MIA40FLAG, we identified a cysteine-rich protein
COA7 with high abundance and specificity (Fig 1A, Dataset EV1).
COA7 is very distinct from classic MIA40 substrates due to the
presence of 13 cysteine residues that are neither surrounded by
classic MIA40-targeting signals like mitochondria IMS-sorting signal
(MISS)/IMS-targeting signal (ITS) (MISS/ITS) nor arranged in clas-
sic motifs (CX3C or CX9C) (Milenkovic et al, 2009; Sideris et al,
2009). Immunoblotting of the MIA40FLAG eluate fraction with COA7
antibody confirmed our mass spectrometry readout (Fig 1B, lane
4). As a positive control, we observed co-purification of ALR and
AIF in the eluate fraction (Fig 1B, lane 4) as well as weak signal of
transiently interacting substrates of MIA40 such as TIMM10B and
TIMM13 (Fig EV1A). To verify the possible interaction between
COA7 and ALR (a known MIA40 partner), we performed affinity
purification via ALRFLAG, and only a small amount of COA7 co-
purified with ALR (Fig EV1B).
COA7 interacts with MIA40 through disulfide bonds
Since MIA40 interacts with many precursor proteins via disulfide
bonds, we investigated whether the interaction with COA7 involves
the formation of disulfide bridges. We first performed affinity purifi-
cation via MIA40FLAG and probed the eluate fraction using MIA40
and COA7 antibodies under reducing (dithiothreitol [DTT]) and
non-reducing (iodoacetamide [IAA]) conditions. Immunoblotting
against both COA7 and MIA40 revealed a band of approximately
45 kDa (Fig 1C, lanes 2 and 3) under non-reducing conditions,
which would match the combined molecular weight of a covalent,
disulfide-bonded complex of MIA40FLAG (15.9 kDa) and COA7
(25.7 kDa). Therefore, we assumed that COA7 may interact with
MIA40 through disulfide bonds. We tested this hypothesis using
mitochondria that were isolated from cells induced to express wild-
type and cysteine residue mutant versions of MIA40FLAG, namely
C53S, C55S, and C53,55S (denoted SPS), under non-reducing condi-
tions (Fig EV1C). We observed two bands that represented native
MIA40-COA7 and MIA40FLAG-COA7 complexes in cells that
expressed wild-type and C53S MIA40FLAG (Fig EV1C, lanes 2, 3, 7,
and 8) and only one band that corresponded to the native MIA40-
COA7 complex in cells that expressed C55S MIA40FLAG and SPS
MIA40FLAG, respectively (Fig EV1C, lanes 4, 5, 9, and 10). We also
confirmed this observation in cellular protein extract that was
probed with anti-COA7 antibody. This indicated the existence of a
covalently bound complex between MIA40 and COA7 under in vivo
conditions (Fig EV1D). The second cysteine residue in the CPC
motif of MIA40 was previously shown to be crucial for the interac-
tion with classic MIA40 substrates (Banci et al, 2009). Therefore,
we checked the cysteine dependency of COA7 binding by perform-
ing affinity purification via MIA40 cysteine mutant protein (C53S,
C55S, and SPS) that was induced in Flp-In T-REx 293 cells. We
observed COA7 only in the eluate fractions of wt MIA40FLAG and
C53S MIA40FLAG (Fig 1D, lanes 6 and 7) and not in the other
mutants (Fig 1D, lanes 9 and 10). Thus, the second cysteine of the
CPC motif (i.e., C55) was crucial for the disulfide bonding of MIA40
with COA7.
COA7 exists as an oxidized protein in the IMS
COA7 contains 13 cysteine residues. Hence, we evaluated the phylo-
genic diversity of cysteine residues in COA7 orthologs in eukaryotes
and found the strong conservation of ten residues (C28, C37, C62,
C71, C110, C111, C142, C150, C182, and C190) across eukaryotes,
whereas three other cysteine residues (C24, C95, and C172) were
present only in vertebrates (Appendix Fig S1A). We hypothesized
that the conserved cysteine residues may be involved in intramolec-
ular disulfide bonds. To predict the cysteine residues that are
involved in the disulfide bonds, we modeled the structure of COA7
based on three proteins with high sequence similarity: Helicobacter
cysteine-rich protein C (1OUV), Helicobacter pylori cysteine-rich
protein B (4BWR), and a protective antigen that is present in Escher-
ichia coli (1KLX). The modeled structure of COA7 possessed five
disulfide bonds with a unique pattern (disulfide bridges between
cysteine residues that were separated by nine or eleven amino
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acids). The structure resembled those of the template proteins with
subsequent helix-turn-helix (HTH) motifs that formed a super-
helical structure that was analogous to previously reported struc-
tures. The N-terminal part of the protein did not have a proper
template. Therefore, we modeled it de novo and manually adjusted
the improperly modeled C24–C37 disulfide bridge to C28–C37. This
modification was based on the following: (i) It fit the evolutionary
conservation of cysteine residues, and (ii) formation of the C28–C37
bond concurs with the pattern of other disulfide bonds (i.e., cysteine
separated by nine or 11 amino acids) in the protein. Hence, we
proposed that the remaining three cysteine residues (C24, C95, and
C172) were expected to be in a reduced state (Appendix Fig S1B).
To validate our prediction of the COA7 redox state, we
employed direct and indirect thiol trapping assays on the mito-
chondria that were isolated from human embryonic kidney 293
(HEK293) cells. The direct thiol trapping assay is based on the dif-
ferential use of alkylating agents that bind free thiol residues in
proteins and modify their migration in sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS–PAGE). Binding of the
low-molecular-mass agent IAA is neutral, whereas modification
with 4-acetamido-4-maleimidylstilbene-2,2-disulfonic acid (AMS)
alters the molecular mass of the protein by 0.5 kDa per each thiol
residue. In the direct thiol assay, AMS modified the migration of
COA7 compared with IAA by approximately 1.5 kDa, which corre-
sponds to three free thiol residues (Fig 2A, lanes 2 and 3). There-
fore, we presumed that ten cysteine residues would be involved in
the disulfide bond, and the remaining three could be in a reduced
state. To test this hypothesis, we performed an indirect thiol trap-
ping assay that involved two-step thiol modification. Free thiols
were first blocked with IAA, and the remaining cysteine residues
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Figure 1. COA7 interacts with MIA40 by disulfide bonding.
A Protein abundance is the normalized signal intensity (LFQ) for a protein divided by its molecular weight. Specificity (enrichment) is the ratio of the protein LFQ
intensity in the MIA40FLAG fraction to control samples. The LFQ for proteins that were not detected in the control samples was arbitrarily set to 1 for calculation
purposes. LFQ, label-free quantification; M.W., molecular weight.
B Flp-In T-REx 293 cells induced to express MIA40FLAG were solubilized, and the affinity purification of MIA40FLAG was performed. Fractions were analyzed by SDS–PAGE
and Western blot. Load: 2.5%. Eluate: 100%. Unbound: 2.5%.
C Flp-In T-REx 293 cells induced to express MIA40FLAG were solubilized, and the affinity purification of MIA40FLAG was performed. Eluate fractions were solubilized
under reducing (DTT) or non-reducing (IAA) conditions and analyzed by SDS–PAGE and Western blot. DTT, dithiothreitol; IAA, iodoacetamide. Eluate: 100%.
D Cellular protein extracts from Flp-In T-REx 293 cells with induced expression of wild-type or mutant MIA40FLAG were subjected to affinity purification. Load and
eluate fractions were analyzed by reducing SDS–PAGE and Western blot. Load: 2.5%. Eluate: 100%.
Source data are available online for this figure.
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that formed disulfide bridges were reduced with DTT and modified
with AMS. The observed shift corresponded to cysteine residues
that formed disulfide bridges in native COA7 (Fig 2B, lane 4). As
expected, we observed migration that corresponded to approxi-
mately ten cysteine residues. As a control, we treated mitochondria
directly with DTT to completely reduce all native disulfide bonds
and then modified them with AMS (Fig 2B, lane 5). We observed
higher migration of COA7 compared with lane 4. These observa-
tions suggest that among the thirteen cysteine residues, likely ten
are involved in disulfide bonds, and the other three exist in a
reduced state. Based on the thiol trapping experiments and in silico
modeling, we propose that COA7 has five Sel-1 domain-like repeats
that are stabilized by disulfide bridges. The Sel-1 domains are char-
acterized by a specific arrangement of cysteine residues (i.e., the
fourth amino acid and fifth amino acid from the last amino acid in
each domain is always a cysteine).
To analyze the submitochondrial localization of COA7, we
performed hypo-osmotic swelling of mitochondria that were isolated
from HEK293 cells. In intact mitochondria, COA7 was preserved
from degradation, similar to other proteins that were localized
inside mitochondria, such as ALR and coproporphyrinogen oxidase
(CPOX) (IMS), TIMM22, and COX6B (IM), and HSP60 and ATP5A
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Figure 2. COA7 is an oxidized protein in the intermembrane space of human mitochondria.
A Schematic representation of the thiol trapping assay. Mitochondria were solubilized in sample buffer with either dithiothreitol (DTT), iodoacetamide (IAA), or
4-acetamido-4-maleimidylstilbene-2,2-disulfonic acid (AMS). The samples were analyzed by SDS–PAGE and Western blot.
B Indirect thiol trapping assay. Mitochondria were pretreated with IAA as indicated to block free cysteine residues, and disulfide bonds were subsequently reduced by
DTT. Mitochondria were solubilized in sample buffer with AMS.
C Localization of mitochondrial proteins analyzed by limited degradation by proteinase K in intact mitochondria (250 mM sucrose), mitoplasts (5 mM sucrose), and
mitochondrial lysates (1% Triton X-100). The samples were analyzed by SDS–PAGE and Western blot. Mitos, mitochondria; Sup, post-mitochondria supernatant; OM,
outer membrane; IM, inner membrane; IMS, intermembrane space.
D N-SIM super-resolution micrographs of one Z-stack (0.15 lm) orthogonal section (XYZ) of HeLa cells or HeLa cells that stably expressed COA7-HA transfected with
different markers TOMM20-DsRed (OM), COX8A-DsRed (IM), and matrix targeted photoactivatable GFP (Matrix target) labeled with anti-HA, anti-COA7, and Smac/
Diablo (IMS) antibodies. The picture represents the majority population of cells from three independent experiments. Scale bar = 2 lm, scale bar in the magnified
insert = 0.5 lm. The panel shows Pearson’s coefficient in a co-localized volume of different subcompartment combinations with anti-HA or anti-COA7. The data are
expressed as a mean  SD (n = 5). ***P < 0.001 [IMSxEnd vs. IMxEnd P = 0.0001; IMSxEnd vs. MxEnd P = 0.0002], ****P < 0.0001 [OMxHA vs. IMSxHA P < 0.0001;
IMSxHA vs. IMxHA P < 0.0001] (one-way ANOVA). M, matrix; End, endogenous COA7; HA, COA7-HA.
Source data are available online for this figure.
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(matrix). As expected, the OM protein TOMM20 was efficiently
degraded by proteinase K in intact mitochondria (Fig 2C, lanes 1–4).
Upon rupturing the OM by swelling in hypotonic buffer, proteinase
K degrades proteins that are exposed to the IMS, whereas matrix
proteins remain protected. Accordingly, we observed the slight
degradation of IM proteins (TIMM22) that faced the IMS side
(Fig 2C, lanes 5–8). The matrix protein Hsp60 was completely resis-
tant to proteinase K degradation, even upon swelling, and was
degraded only by 1% Triton X-100 treatment (Fig 2C, lanes 9 and
10). Under these conditions, COA7 was present in the supernatant
fraction similar to the soluble IMS proteins like CPOX and ALR and
was sensitive to proteinase K (Fig 2C, lanes 5–8). COA7 has been
previously reported to localize to the IMS or matrix (Kozjak-
Pavlovic et al, 2014; Martinez Lyons et al, 2016). To further confirm
the submitochondrial localization of COA7, we performed micro-
scopy using the structured illumination technique (N-SIM). Several
combinations of antibodies and targeted fluorescent proteins were
used in order to verify the specificity of the observed co-localization.
In particular, we targeted fluorophores to a single mitochondrial
subcompartment and observed positive co-localization in the case
of OM × OM (TOMM20 and TOMM20), IM × IM (SDHA and
COX8A), and matrix × matrix (ACO2 and matrix target green fluo-
rescent protein [GFP]) (Appendix Fig S1C). Conversely, we
observed no co-localization when different subcompartments were
stained: OM × IMS (TOMM20 and SMAC), OM × IM (SDHA and
TOMM20), IM × matrix (COX8A and matrix target GFP),
IMS × matrix (SDHA and MDH2), and OM × matrix (TOMM20 and
matrix target GFP) (Appendix Fig S2C). These observations indi-
cated that the technique provided sufficient resolution (~110 nm) to
pair the correct subcompartment combinations of the positive
controls TOMM20 × TOMM20 (OM × OM), COX8A × SDHA
(IM × IM), and matrix target GFP × ACO2 (matrix × matrix) from
all of the combinations that were used as negative controls. We then
compared the signal of COA7 with the markers of different mito-
chondrial subcompartments. We observed an increase in co-locali-
zation only with the IMS marker SMAC and not with markers of
other subcompartments (Fig 2D). The IMS localization of COA7 was
similar with both endogenous COA7 and HA-tagged overexpressed
COA7. Altogether, these findings indicate that COA7 is a soluble
protein of the IMS (Fig 2D).
COA7 does not influence the MIA pathway
The relatively strong interaction between COA7 and MIA40 (see
Figs 1B and EV1A) prompted us to explore the potential role of
COA7 in the MIA pathway. We first examined the steady-state levels
of mitochondrial proteins upon COA7 overexpression and found no
changes in the levels of MIA40 or its dependent proteins, including
ALR, COX6B, and TIMM22 (Fig 3A). We next investigated the influ-
ence of COA7 on the import of MIA40 substrates by importing two
substrates, TIMM8A (CX3C) and COX19 (CX9C), into mitochondria
that have overexpressed levels of COA7. We did not observe any
significant difference in the import of TIMM8A or COX19 compared
with the control (Fig 3B). These observations suggest that COA7
overexpression does not influence either the steady-state levels of
MIA40 or the import of MIA40 substrates.
Cysteine residues in the CPC motif of MIA40 are crucial for the
recognition and import of MIA40 substrates. We previously
established that the second cysteine in the CPC motif of MIA40 is
crucial for the interaction with COA7 (Figs 1D and EV1C and D).
Therefore, we evaluated the levels of free MIA40 that is available
for the import of substrates under non-reducing conditions. As
expected, COA7 overexpression did not significantly affect the level
of free MIA40 (Fig 3C, lanes 2 and 4). We next checked the oxida-
tion state of the cysteine residues in the CPC motif of MIA40 upon
COA7 overexpression using the thiol-binding reagent PEG-PCMal,
which induces a shift of approximately 5 kDa per cysteine residue.
The specificity of the observed bands was confirmed in cells that
had genetically lower levels of MIA40 (Appendix Fig S2A and B).
We verified oxidation of the CPC motif of MIA40 in total cells and
in mitochondria that were isolated from cells that transiently over-
expressed COA7 (Fig 3D, Appendix Fig S2C and D). The treatment
yielded two bands that were specific to MIA40. The lower band
corresponded to the migration of MIA40 with PEG-PCMal that was
bound to one cysteine residue (C4). The second band corresponded
to the binding of PEG-PCMal to three cysteine residues (C4, C53,
and C55). The CPC motif of MIA40 was oxidized to a similar extent
in COA7-overexpressed and control samples although an overall
level of oxidation was higher in isolated mitochondria than in total
cells (Fig 3D, lanes 3 and 4, Appendix Fig S2D, lanes 1 and 2)
which is consistent with partial oxidation of proteins during mito-
chondria isolation (Topf et al, 2018). Thus, we confirmed that
COA7 overexpression did not affect the redox state of cysteine resi-
dues in the CPC motif, suggesting that both cysteine residues were
equally available for importing MIA40 substrates, such as TIMM8A
and COX19. This observation complemented our previous finding
that COA7 overexpression did not affect the import of MIA40
substrates.
The role of ALR in the MIA pathway is well established, and
the interaction between MIA40 and ALR is crucial for maintaining
MIA40 activity (Banci et al, 2012; Sztolsztener et al, 2013). To
investigate whether COA7 influences this crucial interaction, we
performed affinity purification via MIA40FLAG to evaluate the
MIA40-ALR interaction upon COA7 overexpression. The levels of
ALR that co-purified with MIA40 were similar in cells that tran-
siently overexpressed COA7 and control cells (Fig 3E, lanes 1 and
2). We did not observe any difference in the MIA40-ALR interac-
tion under COA7-knockdown conditions (Fig EV2A). Consequently,
COA7 knockdown using two different oligonucleotides did not alter
the levels of MIA40 or its substrates, such as COX6B, TIMM9, and
TIMM22 (Fig EV2B). We also examined the MIA40-ALR interaction
by affinity purification via ALRFLAG under similar conditions. The
amount of MIA40 that co-purified with ALR was similar under
conditions of both COA7 knockdown and overexpression
(Fig EV2C and D). Thus, we conclude that COA7 neither influences
MIA pathway activity nor the import of MIA40 substrates to the
IMS.
MIA40 facilitates the import of COA7 into mitochondria
To investigate whether MIA40 is involved in the import of COA7,
we performed in organello import of radiolabeled [35S]COA7
precursor into mitochondria that were isolated from cells that were
induced to express MIA40FLAG. We observed a significant increase
in COA7 import in mitochondria with MIA40FLAG compared with
the control (Fig 4A). As a positive control, import of the classic
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MIA40 substrate TIMM8A was significantly augmented by
MIA40FLAG overexpression (Fig 4B). Predictably, we also observed
a significant increase in steady-state levels of COA7, similar to
other classic MIA40-dependent proteins (e.g., COX6B and ALR;
Fig 4C). Thus, we conclude that COA7 is imported by the MIA
pathway and behaves like an MIA40 substrate. Considering the fact
that ALR is an integral part of the MIA pathway, we also investi-
gated whether ALR overexpression stimulates the import of COA7.
Contrary to MIA40 overexpression, the import of COA7 was similar
in ALR-overexpressed mitochondria compared with control mito-
chondria (Fig 4D). Likewise, ALR overexpression did not alter the
import of TIMM8A (Fig 4E). In agreement with the import results,
steady-state levels of COA7 and MIA40-dependent proteins did not
increase upon ALR overexpression (Fig 4F). We also examined the
influence of MIA40 depletion on COA7 biogenesis. MIA40 knock-
down using two different oligonucleotides decreased nearly 90% of
MIA40 in HeLa cells (Fig 5A). As expected, the levels of COA7
were significantly reduced, similar to ALR and other substrates
(e.g., COX6B and TIMM9). Proteins that are unrelated to the MIA
pathway, such as actin, GAPDH, and ATP5A, were unchanged in
MIA40 knockdown cells. This further substantiated the role of
MIA40 in the biogenesis of COA7. Interestingly, ALR knockdown
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also affected the steady-state levels of COA7 and MIA40-dependent
proteins (Fig 5B).
To further substantiate the involvement of the MIA pathway in
the import of COA7, we developed a cell line with deletion of the
CPC motif in only one allele of the gene (HEK293 MIA40 WT/
Del53-60) (Fig 5C, Dataset EV2 and EV3). The Western blot analysis
of HEK293 MIA40 WT/Del53-60 cells revealed two bands that were
specific to MIA40 (wild-type MIA40 and Del53-60 MIA40; Fig 5D). In
this cell line, the levels of wild-type MIA40 were partially affected
by the presence of mutant allele suggesting a dominant negative
effect of the mutation. In parallel, we observed lower levels of
MIA40 substrates, including COX6B, TIMM9, and TIMM22. The
levels of other mitochondrial proteins, such as MIC19 and ATP5A,
remained unchanged (Fig 5D). The decrease in MIA40-dependent
proteins was successfully rescued by the exogenous overexpression
of MIA40 (Fig 5E, lanes 3 and 4). Thus, we established that the
observed phenotype was specific to MIA40 depletion. Furthermore,
we used mitochondria that were isolated from MIA40 WT/Del53-60
to measure the import of radiolabeled [35S]COA7. The import effi-
ciency of COA7 was reduced to almost 50% in these mutant cells
when compared with wild-type cells (Fig 5F). We also observed a
40% reduction of the import of the classic MIA40 substrate TIMM8A
(Fig 5G). Again, these observations indicate that COA7 utilizes the
MIA40 pathway for import into mitochondria, and it is a newly
identified non-canonical substrate of MIA40.
COA7 pathological mutants are defective in
mitochondrial import
Mutations in COA7 are associated with the defective assembly and
function of respiratory chain complexes in patients diagnosed with
mitochondrial encephalopathy (Martinez Lyons et al, 2016; Higuchi
D
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et al, 2018). The first reported case presented with a biallelic
compound heterozygous mutation, which led to two forms of
COA7: COA7 with a single amino acid mutation (COA7-Y137C) and
COA7 with a deletion of exon 2 (COA7-exon2D; Fig 6A). However,
these mutant proteins were undetectable in patient-derived cultured
skin fibroblasts (Martinez Lyons et al, 2016). Therefore, we charac-
terized these COA7 mutants to elucidate the mechanism by which
protein loss occurs under pathological conditions.
In order to do so, we transiently overexpressed wild-type COA7
and its mutant variants (COA7-Y137CHIS and COA7-exon2
D
HIS) in
HEK293 cells. We detected significantly lower levels of both variants
compared with the wild-type (Fig 6B), which is consistent with
protein loss in fibroblasts from patients (Martinez Lyons et al,
2016). Moreover, we observed a decreased level of COA7-exon2DHIS
than COA7-Y137CHIS. Next, we investigated the localization of
mutant proteins to the mitochondria isolated from these cells and
observed a proportional decrease in the mitochondrial fraction
together with a slight increase of the mutant proteins in the cytosolic
fraction (Fig 6C, lanes 3, 9, and 12). Despite only a slight defect in
mitochondrial localization of mutant COA7-Y137CHIS, diminished
steady-state levels of protein support the possibility of degradation.
The mitochondrial fraction of COA7-Y137CHIS presents IMS localiza-
tion, which was confirmed by mitoplasting (Appendix Fig S3A). As
a control, we observed the efficient localization of mitochondrial
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Figure 5. MIA40 is involved in the import and biogenesis of COA7.
A Cellular protein extracts were isolated from HeLa cells transfected with oligonucleotides that targeted different regions of MIA40 mRNA or with control
oligonucleotides. The samples were analyzed by reducing SDS–PAGE and Western blot.
B Cellular protein extracts were isolated from HeLa cells transfected with oligonucleotides that targeted different regions of ALR mRNA or with control
oligonucleotides. The samples were analyzed by reducing SDS–PAGE and Western blot.
C Schematic representation of MIA40 sequence containing the CPC motif in HEK293 MIA40 WT/WT and HEK293 MIA40 WT/Del53-60 cells.
D Cellular protein extracts were isolated from HEK293 MIA40 WT/WT and WT/Del53-60 cells. The samples were analyzed by SDS–PAGE and Western blot.
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Source data are available online for this figure.
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proteins, such as cytochrome c, ATP5A, TOMM20, and HSP60, in
the mitochondrial fraction, whereas the cytosolic protein tubulin
was present only in the cytosolic fraction.
Improperly folded mitochondrial IMS proteins can be substrates
of proteases or can be retro-translocated to the cytosol (Bragos-
zewski et al, 2015). In order to understand the structural features
that contribute to the instability of COA7-Y137C, we performed
molecular modeling and simulation on the mutant protein. Homol-
ogy modeling of the mutant suggested the possibility of two alterna-
tive disulfide bridges (C100-C137 and C111-C137) in addition to the
native disulfide bond (C100-C111) that could potentially destabilize
the structure (Appendix Fig S3B). To further understand the dynam-
ics of the mutant proteins, we subjected the wild-type COA7 and
COA7-Y137C mutants to molecular dynamics simulations, which
revealed greater flexibility in the two loop regions (Q159-K166 and
D198-K202) of the COA7-Y137C (Appendix Fig S3C). We also identi-
fied the possibility of new salt bridge formation between lysine
(K133) and aspartic acid (D136) in the COA7-Y137C mutant
(Appendix Fig S3D). Thus, we propose that the additional cysteine
at the 137th position leads to alternative disulfide bridges that
compete with the native disulfide bond (C100-C111) causing
misfolding and destabilization leading to structural instability,
which can in turn increase the possibility of protein removal from
the IMS. We previously established that COA7 interacts with MIA40
for its efficient import into mitochondria. Therefore, we investigated
the influence of these mutations on the MIA40-COA7 interaction.
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Source data are available online for this figure.
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Affinity purification via COA7-Y137CHIS and COA7-exon2
D
HIS
revealed an uncompromised interaction with MIA40 (Fig 6D, lanes
6–8). The lower level of co-purified MIA40 could be attributed to
lower expression of the mutant variants (Fig 6D, lanes 2–4). Finally,
the in organello import of the COA7 mutants revealed a 50%
decrease in import efficiency for the COA7-Y137C mutant and a
nearly 70% decrease for COA7-exon2D compared with the wild-type
(Fig 6E). Therefore, even though the mutant variants can interact
with MIA40, their import into mitochondria is specifically impaired.
As shown before, the steady-state levels of both mutated proteins
are very low, which could be the result of a combination of their
intrinsic instability, low import efficiency, and the inability of being
productively maintained in the IMS, thus making them a subject of
degradation.
The proteasome degrades cytosol-localized COA7 variants
Mitochondrial IMS proteins are efficiently degraded by the protea-
some either before import or after retro-translocation. We followed
the degradation kinetics of mutant proteins in HEK293 cells tran-
siently transfected with corresponding constructs by performing a
cycloheximide-chase experiment (Fig 7A) and found that the mutant
proteins were degraded faster than wild-type (Fig 7B, lanes 3 and 5,
Appendix Fig S4A). We then evaluated the role of the proteasome in
degradation of mutant proteins in these cells (Fig 7C). Effective inhi-
bition of the proteasome by MG132 was confirmed by an increase in
the ubiquitination of cellular proteins (Appendix Fig S4B). We found
that MG132 treatment did not rescue the degradation of already
synthesized mutant proteins (Fig 7D, lanes 2 and 3). In contrast,
under active translation mutant COA7 was degraded by proteasome,
while wild-type protein was only marginally affected, suggesting that
proteins with slower rate of import to mitochondria were sensitive
to proteasome-mediated degradation (Fig 7D, lanes 4 and 5,
Appendix Fig S4C). Next, we investigated whether the stabilization
of mutant proteins in the cytosol increases their translocation to
mitochondria (Fig 7E). Indeed, in HEK293 transiently expressing
COA7 in the presence of MG132-mediated proteasome inhibition, the
levels of COA7 mutant proteins increased in the cytosol, which was
paralleled by an increased mitochondrial content of the mutant
proteins (Fig 7F, lanes 3, 7, 10, 14). Inhibition of the proteasome
was confirmed by an increase in protein ubiquitination
(Appendix Fig S4D). In order to further verify ubiquitin–proteasome
system involvement in degradation of COA7, we co-expressed
COA7FLAG with His-tagged ubiquitin and performed affinity purifica-
tion via His-tag. We observed specific co-purification of COA7FLAG
with markedly higher molecular weight characteristic for poly-
ubiquitinated proteins (Fig EV3A). Mutant COA7 could also undergo
degradation in the IMS by local proteases such as YME1L. To verify
this hypothesis, we silenced YME1L in immortalized fibroblasts that
were derived from the subject expressing pathogenic variants in
COA7 (mt4229i) (Martinez Lyons et al, 2016). We observed only a
moderate increase in both mutants of COA7 upon YME1L silencing
(Fig EV3B). Of note, in the immortalized fibroblasts the lower
levels of COA7-exon2D in comparison with COA7-Y137C were
observed. A similar phenomenon was noted in HEK293 under
transient expression of COA7 variants, suggesting that the observed
effect reflects specific propensities of these proteins and not a
crosstalk between them.
Rescue of COA7 mutant proteins in a patient cell line upon
proteasome inhibition
We inhibited the proteasome machinery in mt4229i fibroblasts
derived from patients with MG132 and other two clinically used
proteasome inhibitors (bortezomib and carfilzomib). Proteasome
inhibition increased the levels of both the mutation-carrying COA7
proteins (COA7-Y137C and COA7-exon2D) in the patient cells
(Fig 8A). As a control for the experiment, we also observed an
increase in the levels of HSP70 upon treatment with proteasome
inhibitors as reported previously (Kim et al, 1999; Awasthi &
Wagner, 2005). Interestingly, upon inhibition we also observed an
increase in the levels of COX6A and COX6B, the structural subunits
of complex IV which are affected in the patient. Further, we tested
the localization of COA7 variants upon proteasome inhibition and
observed an increase in their localization to mitochondria (Fig 8B).
These results together with the previous findings using HEK293 cells
substantiated the involvement of the proteasome in the degradation
of misfolded/mislocalized mitochondrial proteins. Thus, we con-
firmed the influence of the proteasome system on protein levels
under pathological conditions. Since proteasome inhibition
increased COA7 levels inside mitochondria, we tested whether this
could rescue the complex IV deficiency of patient cells (Martinez
Lyons et al, 2016). Patient fibroblast presented 40% lower activity
of complex IV than control fibroblasts (Fig 9A). Treatment of patient
fibroblasts with proteasome inhibitors led to approximately 35%
increase in complex IV activity (Fig 9B). To further verify whether
the observed significant effect was attributable to higher levels of
COA7, we combined bortezomib treatment with the overexpression
of wild-type and the two different mutant versions of COA7. Fibrob-
lasts that expressed wild-type COA7 and COA7-Y137C exhibited a
significant 50% increase in complex IV activity, and COA7-exon2D
expression did not rescue the defective phenotype (Fig 9C). This
strongly suggests that COA7-Y137C is a functionally competent
protein that can effectively modulate the activity of complex IV if
allowed to reach the IMS. Accordingly, neither of pathogenic
mutants of COA7 had a negative effect on levels of complex IV subu-
nits and on its activity when overexpressed in HEK293 cells in the
presence of the native COA7 (Appendix Fig S5A and B). Thus, the
defective phenotype that is observed in this patient is principally
due to mislocalization and/or premature degradation of proteins by
the proteasome system.
We then verified whether the rescue of complex IV activity by
proteasome inhibition increased cell growth in oxidative phospho-
rylation-promoting galactose media. In the control fibroblasts,
small concentrations of bortezomib (up to 2.5 nM) did not
influence cell growth after 24 h in galactose media (Appendix Fig
S5C). Interestingly, this was not the case for the patient fibrob-
lasts that showed a tendency to an increase in growth
(Appendix Fig S5D).
We further intended to analyze the levels of the respiratory
chain complexes in the patient cells upon proteasome inhibition.
Initially, when comparing patient cells with healthy control fibrob-
lasts, the BN-PAGE analysis revealed a marked defect in the
assembly of supercomplexes in patient cells observed with various
antibodies (Fig 9D). In order to further confirm the role of COA7
in the observed increase in supercomplex formation, we overex-
pressed the wild-type COA7 and COA7-Y137C in patient
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fibroblasts. We analyzed cell extracts via BN-PAGE and confirmed
an increased presence of supercomplexes (CI + CIII2 and
CI + CIII2 + CIV) whenever wild-type COA7 or COA7-Y137C were
overexpressed (Fig 9E).
We then verified whether the inhibition of proteasome could
restore the formation of supercomplexes in the patient fibroblasts.
Upon proteasome inhibition, we observed an increase in supercom-
plex formation using antibodies directed to complex I (NDUFS1),
complex III (RIESKIE and UQCR1), and complex IV (COX4 and
COX5B) (Fig 9F). Thus, we propose that the degradation of slow-
import mutant COA7 can be prevented by proteasome inhibition
leading to partial restoration of COA7 levels in mitochondria and of
respiratory chain function (Fig 10).
Discussion
The present study established a recently identified IMS protein,
COA7, as a non-canonical substrate of MIA40. COA7 exists as an
oxidized protein in the IMS of mitochondria, and MIA40 facilitates
its import into IMS (Fig 10). Whole-exon sequencing of a patient
who was diagnosed with leukoencephalopathy recently revealed
biallelic heterozygous mutations of COA7 that led to absence of the
protein (Martinez Lyons et al, 2016). We discovered that the protea-
some-mediated degradation of pathogenic COA7 mutant proteins
accounted for nearly the complete absence of the protein. When
cells expressing both point mutation and deletion instable COA7
proteins were treated with proteasome inhibitors, the degradation of
A
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the mutated proteins was prevented and their localization to mito-
chondria was increased. In the patient-derived cells, this increase in
COA7 levels was associated with an increase in complex IV activity
and improved formation of the respiratory chain supercomplexes
(Fig 10).
Most mitochondrial proteins are translated in the cytosol where
they are inevitably in proximity to the proteasome, which is the
main cytosolic protein quality control machinery. It is known that
proteasome is involved in degradation of several proteins from the
outer mitochondrial membrane and the IMS (Pearce & Sherman,
1997; Zhong et al, 2005; Azad et al, 2006; Yonashiro et al, 2006;
Karbowski et al, 2007; Neutzner et al, 2008; Radke et al, 2008;
Ziviani et al, 2010; Bragoszewski et al, 2015). Mitochondrial
proteins undergo proteasomal degradation as a turnover mechanism
of mature proteins but also as an effect of mislocalization during
mitochondrial protein biogenesis. Upon the failure of mitochondrial
protein import, excess mitochondrial precursor proteins in the
cytosol are eliminated by the proteasome-mediated degradation
prior to their import (Bragoszewski et al, 2013; Wrobel et al, 2015).
Moreover, substrates of the MIA pathway in yeast were found to be
ubiquitinated and accumulated in response to proteasome inhibi-
tion, even in the presence of active import machinery (Bragoszewski
et al, 2013; Kowalski et al, 2018). Thus, the proteasome system acts
as a vital checkpoint for the improper localization of proteins and
promotes efficient mitochondrial IMS protein biogenesis (Bragos-
zewski et al, 2013, 2017). The present data demonstrate that
mislocalized COA7 is more prone to degradation. Interestingly,
interaction of mutant variants of COA7 with MIA40 raises the possi-
bility that they follow retro-translocate-mediated degradation due to
inefficient folding and accumulation in mitochondria (Bragoszewski
et al, 2015).
In the present study, we characterized two pathogenic mutants
of COA7 that are associated with mitochondrial leukoencephalopa-
thy. These proteins were less efficiently imported into mitochon-
dria, which led to proteasomal degradation in the cytosol.
Inhibition of the proteasome rescued mutant protein levels and
increased their mitochondrial levels, accompanied by higher levels
of complex IV subunits (e.g., COX6B and COX6A) and an increase
in the activity of complex IV. The recovery of complex IV activity
was also achieved by the overexpression of COA7-Y137C protein,
suggesting that the mutant protein, if allowed to be imported into
mitochondria, was sufficiently active to ameliorate the pathological
phenotype. Analogously, other studies reported that the overex-
pression of mutant versions of mitochondrial proteins, such as
NUBPL and FOXRED1, was able to reverse the pathological pheno-
type in patient cells (Tucker et al, 2012; Formosa et al, 2015). The
stimulation of mitochondrial import of the pathogenic mutant
CHCHD10 was recently proposed as a possible therapeutic strategy
for amyotrophic lateral sclerosis (Lehmer et al, 2018). Our data
suggest that the inhibition of excessive degradation by the protea-
some can rescue mitochondrial function in diseases that are associ-
ated with the mislocalization and premature degradation of
mitochondrial proteins.
Pathogenic mutations of various mitochondrial proteins (e.g.,
NDUFAF3, NDUFAF4, FOXRED1, COA5, COA6, COX6B, CHCHD10,
and tafazzin) were associated with the secondary loss of other mito-
chondrial proteins, which can aggravate the disease (Nouws et al,
2012; Dudek et al, 2013; Modjtahedi & Kroemer, 2016). In patient-
derived fibroblasts, structural subunits of cytochrome c oxidase
COX6A and COX6B decreased in parallel with COA7 and were
rescued by proteasome inhibition. Thus, proteasome inhibition not
only rescued COA7 levels but also prevented the secondary loss of
mitochondrial proteins. Notably, mitochondrial biogenesis has been
previously shown to be a rescue mechanism for defective mitochon-
dria (Hansson et al, 2004; Kuhl et al, 2017).
Mitochondrial diseases affect approximately one in 2,000 people
and may arise at any age with a wide range of clinical symptoms
(Gorman et al, 2016; Suomalainen & Battersby, 2018). Among these
diseases are several genetic mitochondrial pathologies that are asso-
ciated with the apparent loss of mutated proteins that are often
A
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Figure 8. Inhibition of the proteasome rescues the mitochondrial levels of COA7 in patient-derived fibroblasts.
A Cellular protein extracts were isolated from immortalized patient-derived skin fibroblasts that were treated with the indicated concentrations of MG132, bortezomib,
or carfilzomib. The samples were analyzed by reducing SDS–PAGE and Western blot.
B Cellular fractions were prepared from immortalized patient-derived skin fibroblasts that were treated with the indicated concentrations of MG132, bortezomib, or
carfilzomib. The samples were analyzed by reducing SDS–PAGE and Western blot. T, total; C, cytosol; M, mitochondria.
Source data are available online for this figure.
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associated with the more generalized deficiency of mitochondrial
protein biogenesis (Modjtahedi & Kroemer, 2016). Despite dramatic
improvements in the genetic and metabolic diagnoses of these
severe progressive diseases, no curative treatments have been
discovered. The current treatment regimen for respiratory chain
deficiency is mostly metabolite supplementation with CoQ10, crea-
tinine, or riboflavin, which is only a symptomatic treatment and
does not ameliorate the underlying pathological condition. In the
present study, we used bortezomib and carfilzomib (i.e., two
proteasome inhibitors that have been approved for the treatment of
patients with multiple myeloma and mantle cell lymphoma) to
reverse the pathological phenotype in fibroblasts that were derived
from a patient who suffered from mitochondrial leukoencephalopa-
thy. The possibility of using clinically approved inhibitors, such as
bortezomib, against this type of disease requires careful considera-
tion due to possible side effects (Cavaletti et al, 2007; Nowis et al,
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Figure 9. Inhibition of the proteasome rescues the activity and assembly of the respiratory complexes.
A Complex IV activity was assessed by oxidation of cytochrome c in digitonized cellular extracts from the immortalized patient-derived skin fibroblasts and control
healthy fibroblasts. The results of three biological replicates were quantified and normalized to control fibroblasts. Data are expressed as a mean  SEM (n = 3,
*P = 0.01) (two-tailed Student’s t-test).
B Complex IV activity was assessed by oxidation of cytochrome c in digitonized cellular extracts from immortalized patient-derived skin fibroblasts treated with MG132
(1 lM), bortezomib (20 nM), or carfilzomib (50 nM) for 12 h and recovered for another 6 h. The results of three biological replicates were quantified and normalized
to DMSO-treated samples, and the data are expressed as a mean  SEM (n = 3, *P = 0.04 [DMSO vs MG132], **P = 0.0025 [DMSO vs Bortezomib], *P = 0.02 [DMSO
vs Carfilzomib]) (two-tailed Student’s t-test).
C Immortalized patient-derived skin fibroblasts transiently expressing wild-type or mutant COA7 (COA7-Y137C and COA7-Ex2Δ) for 48 h were treated with bortezomib
(20 nM) during the last 12 h. The fibroblasts were harvested, and complex IV activity was measured in digitonized cellular extracts. The results of three biological
replicates were quantified and normalized to empty vector bortezomib-treated samples, and the data are expressed as a mean  SEM (n = 3, *P = 0.01 [Empty
vector vs. COA7- Wt], *P = 0.005 [Empty vector vs COA7 – Y137C]) (two-tailed Student’s t-test).
D Mitochondria isolated from control and patient fibroblast were solubilized in digitonin buffer and analyzed by 4–13% gel BN-PAGE and Western blot. SC,
supercomplexes.
E Immortalized patient-derived skin fibroblasts transfected with plasmid encoding wild-type COA7HIS or COA7-Y137CHIS were solubilized in DDM buffer and analyzed by
4–13% gel BN-PAGE and Western blot.
F Mitochondria were isolated from immortalized patient-derived skin fibroblasts treated with bortezomib (10 nM) for 12 h and recovered for another 6 h.
Mitochondria were solubilized in digitonin buffer and analyzed by 4–13% gel BN-PAGE and Western blot. SC, supercomplexes.
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2010; Zheng et al, 2012; Kaplan et al, 2017). Yet, the severity of
mitochondrial diseases prompts us to suggest that proteasome inhi-
bitors may be applied in the course of a therapeutic intervention to
treat mitochondrial diseases that are associated with the reduced
steady-state levels and excessive degradation of mitochondrial
proteins by the proteasome that are primarily attributable to the
pathogenic mutations (Fig 10).
Materials and Methods
Cell lines and growth conditions
HeLa, HEK293, and Flp-In T-REx 293 cells were cultured at 37°C
with 5% CO2 in standard Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% (v/v) heat-inactivated fetal bovine
serum, 2 mM L-glutamine, 100 U/ml penicillin, and 10 lg/ml
streptomycin sulfate. Flp-In T-REx 293 with inducible expression of
MIA40FLAG, MIA40-C53SFLAG, MIA40-C55SFLAG, and MIA40-
C53,55SFLAG (SPS), and ALRFLAG were generated by co-transfection
with pcDNA5/FRT/TO plasmid containing respective cDNA and a
helper plasmid pOG44. Single cell-derived cell lines were obtained
by selection with hygromycin. Expression of respective proteins was
induced by treatment with tetracycline (100 ng/ml) for 24 h. Cell
lines with introduced MIA40-C55SFLAG and SPS showed repro-
ducibly lower levels of expression than MIA40FLAG and MIA40-
C53SFLAG. Immortalized skin fibroblast cell lines (Ai and mt4229i)
were grown in standard DMEM supplemented with 10% (v/v) heat-
inactivated fetal bovine serum, 2 mM L-glutamine, 100 U/ml peni-
cillin, 10 lg/ml streptomycin sulfate, 1 mM sodium pyruvate, and
50 lg/ml uridine. The MIA40 deletion cell line (HEK293 MIA40
WT/Del Del53-60) was generated using guide RNA that targeted exon
3 of MIA40 ORF cloned into the pX330 vector (Addgene, 42230).
The recombinant plasmid was co-transfected into HEK293 cells with
green fluorescent protein (GFP)-expressing plasmid. Single cells that
expressed GFP were sorted into each well of the 96-well plate and
grown at 37°C under 5% CO2. Deletion that corresponded to amino
acids 53–60 of MIA40 was confirmed by sequencing and CRISPR ID
analysis. Where indicated, cells were grown in DMEM that
contained low glucose (1.1 g/l) or galactose (1.8 g/l) as described
below.
Human samples
Immortalized skin fibroblast cell lines (Ai and mt4229i) reported in
Martinez Lyons et al (2016), were obtained from the BioBank of
Telethon Italy located at the Fondazione Istituto Neurologico Carlo
Besta, Milan, Italy. Informed consent was obtained from all
subjects. All the procedures involving human samples conformed to
the principles set out in the WMA Declaration of Helsinki and the
Department of Health and Human Services Belmont Report.
DNA and siRNA transfection
For protein overexpression, HEK293 cells were seeded at
0.07 × 106/cm3 and grown in low-glucose DMEM for 24 h. Medium
was exchanged to galactose DMEM, and cells were transfected with
0.05 lg/cm3 pcDNA3.1(+) containing the gene of interest mixed
with 0.1 ll/cm3 Gene Juice Transfection Reagent (70967; Merck
Millipore) according to the manufacturer’s protocol. Cells were incu-
bated at 37°C and 5% CO2 for 24 h. Cells transfected with empty
pcDNA3.1 (+) were used as a control.
For gene knockdown, the following mRNA sequences were
targeted: MIA40_1 (50-ATAGCACGGAGGAGATCAA-30), MIA40_2
(50-GGAATGCATGCAGAAATAC-30), ALR_1 (50-GGAGTGTGCTGA
AGACCTA-30), ALR_2 (50-GCATGCTTCACACAGTGGCTGT-30), COA
7_1 (50-GATGGTGTTGATAAGGATGA-30), and COA7_2 (50-GGCAC
ATGATGGACAGGTTAA-30), YME1L (50-GATGCATTTAAAACTG
GTTTT-30). The transfection of HEK293 cells was performed in low-
glucose DMEM using oligofectamine as per the manufacturer’s
instructions. After 24 h in low glucose, the medium was changed to
galactose-containing DMEM for the next 48 h and cells were
harvested. As a control, the cells were transfected with Mission
siRNA universal negative control (SIC001, Sigma).
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Figure 10. The role of MIA pathway and proteasome in the biogenesis of COA7.
A The precursor form of wild-type COA7 is synthesized in the cytosol and imported into the mitochondrial intermembrane space by the MIA pathway, where it is
involved in the respiratory chain biogenesis.
B The precursor form of mutant COA7 is import-defective, and therefore, it is degraded in the cytosol by proteasome.
C Proteasome inhibition rescues the mitochondrial import of mutant COA7 as well as the biogenesis and function of the respiratory chain.
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Antibodies
The antibodies against following proteins were used in the study:
actin (Sigma, A1978, 1:500), ALR (Santa Cruz Biotechnology, Sc-
134869, 1:500), ATP5A (Abcam, ab14748, 1:500), COA7 (Sigma,
HPA029926, 1:500), COX4 (Abcam, ab14744, 1:500, and Cell Signal-
ing Technology, 4850, 1:2,000), COX5B (Santa Cruz Biotechnology,
Sc-374417, 1:500), COX6A (Rabbit Serum, 3282.7, 1:1,000), COX6B
(Abcam, ab110266, 1:500), COX17 (Proteintech, 11464-1-AP,
1:100), GAPDH (Santa Cruz Biotechnology, Sc-47724, 1:1,000),
HSP60 (Sigma, H4149, 1:500), MIA40 (Rabbit Serum, WA136-5,
1:500), MIC60 (Novus Biologicals, NB100-1919, 1:1,000), NDUFS1
(Santa Cruz Biotechnology, Sc-50132 1:1,000), SDHB (Santa Cruz
Biotechnology, Sc-25851, 1:500), TIMM9 (Abcam, ab57089, 1:200),
TIMM22 (Proteintech, 14927-1-AP, 1:500), TOMM20 (Santa Cruz
Biotechnology, Sc-11415, 1:500), SDHA (Santa Cruz Biotechnology,
Sc-166947, 1:1,000), YME1L (Proteintech, 11510-1-AP, 1:100), ubiq-
uitin (Santa Cruz Biotechnology, Sc-8017, 1:500), UQCR1 (Sigma,
HPA002815, 1:500).
Cellular protein lysate
Cells were harvested and lysed in radioimmunoprecipitation assay
(RIPA) buffer (65 mM Tris–HCl [pH 7.4], 150 mM NaCl, 1% v/v NP
40, 0.25% sodium deoxycholate, 1 mM ethylenediaminetetraacetic
acid [EDTA], and 2 mM phenylmethylsulfonyl fluoride [PMSF]) for
30 min at 4°C. The lysate was clarified by centrifugation at
14,000 × g for 30 min at 4°C. The supernatant was collected, and
the protein concentration was measured by the bicinchoninic acid
protein assay (Thermo Fisher Scientific). The supernatant was
diluted in Laemmli buffer that contained either 50 mM DTT or
50 mM IAA for reducing and non-reducing conditions, respectively.
Mitochondrial isolation and fractionation
HEK293 cells were harvested and resuspended in ice-cold trehalose
buffer (10 mM HEPES-KOH [pH 7.7], 300 mM trehalose, 10 mM
KCl, 1 mM EDTA, and 1 mM ethylene glycol-bis[b-aminoethyl
ether]-N,N,N’,N’-tetraacetic acid [EGTA]) supplemented with 2 mg/
ml bovine serum albumin (BSA) and 2 mM PMSF. After homoge-
nization in a Dounce glass homogenizer (Sartorius), the homoge-
nate was clarified by centrifugation at 1,000 × g for 10 min at 4°C.
The supernatant was centrifuged at 10,000 × g for 10 min at 4°C.
The pellet was resuspended in trehalose buffer without BSA, and
protein levels were quantified using the Bradford assay.
Human fibroblasts were harvested and resuspended in ice-cold
isotonic buffer (10 mM MOPS [pH 7.2], 75 mM mannitol, 225 mM
sucrose, and 1 mM EGTA) supplemented with 2 mg/ml BSA and
2 mM PMSF, and subjected to centrifugation at 1,000 × g for 5 min
at 4°C. The cell pellet was then resuspended in cold hypotonic
buffer (10 mM MOPS [pH 7.2], 100 mM sucrose, and 1 mM EGTA)
and incubated on ice for 5–7 min. The cell suspension was homoge-
nized in a Dounce glass homogenizer (Sartorius). Cold hypertonic
buffer (1.25 M sucrose and 10 mM MOPS [pH 7.2]) was added to
the cell homogenate (1.1 ml/g of cells). The homogenate was
subjected to centrifugation at 1,000 × g for 10 min at 4°C to pellet
the cellular debris. The supernatant that contained mitochondria
was then carefully aspirated and centrifuged again. The supernatant
was then subjected to high-speed centrifugation at 10,000 × g for
10 min at 4°C to pellet mitochondria. The pellet was resuspended in
isotonic buffer without BSA and quantified using the Bradford
assay. Mitochondria were denatured in 2× Laemmli buffer with
50 mM DTT or 50 mM IAA. The samples were separated by SDS–
PAGE and analyzed by Western blot.
For cell fractionation, after homogenization, the supernatant was
then divided into three equal aliquots. One aliquot was saved as the
total fraction. Two aliquots were centrifuged at 10,000 × g for
10 min at 4°C to collect the pellet and supernatant for the mitochon-
drial and cytosolic fractions, respectively. The proteins from the
total and cytosolic fractions were precipitated by pyrogallol red.
Finally, all three fractions were denatured in urea sample buffer
with 50 mM DTT for SDS–PAGE and Western blot.
Mitoplasting
Isolated mitochondria were incubated on ice for 30 min in either
sucrose buffer (250 mM sucrose and 20 mM HEPES/KOH [pH 7.4])
or swelling buffer (25 mM sucrose and 20 mM HEPES/KOH [pH
7.4]). The solution was divided into two equal parts. One part was
treated with proteinase K (25 lg/ml) for 5 min on ice, and another
part was left untreated. Proteinase K was inactivated by the addition
of 2 mM PMSF. Mitochondria were pelleted by centrifugation,
and the supernatant fraction was subjected to pyrogallol red precipi-
tation to recover the proteins. The pellet was then denatured in urea
sample buffer with 50 mM DTT and analyzed by SDS–PAGE and
Western blot.
FLAG-tag affinity purification
A total of 4 × 106 Flp-In T-REx 293 derived cells were seeded and
grown in low-glucose medium for 24 h and then induced with tetra-
cycline (100 ng/ml) in galactose medium for 24 h. The cells were
harvested and solubilized in lysis buffer (50 mM Tris–HCl [pH 7.4],
150 mM NaCl, 10% glycerol, 1 mM EDTA, and 1% digitonin)
supplemented with 2 mM PMSF and 50 mM IAA for 20 min at 4°C.
The lysate was clarified by centrifugation at 20,000 g for 15 min,
and the supernatant was incubated with anti-FLAG M2 affinity gel
(Sigma) for 2 h at 4°C with mild rotation. After binding, the resin
was washed three times with lysis buffer without digitonin. The
column-bound proteins were eluted with either 3X FLAG peptide for
mass spectrometry or Laemmli buffer under reducing or non-redu-
cing conditions for SDS–PAGE and Western blot.
COA7HIS affinity purification
HEK293 cells were grown in low-glucose DMEM for 24 h. The cells
were then transferred to DMEM and transfected with pcDNA3.1(+)-
COA7HIS using Gene Juice Transfection Reagent (Merck Millipore)
according to the manufacturer’s protocol. The cells were harvested
24 h after transfection and solubilized in ice-cold digitonin buffer
(1% digitonin, 10% glycerol, 20 mM Tris–HCl [pH 7.4], 100 mM
NaCl, and 20 mM imidazole [pH 7.4]) supplemented with 2 mM
PMSF and 50 mM IAA for 20 min at 4°C. The lysate was clarified by
centrifugation at 20,000 g for 15 min at 4°C. The supernatant was
then incubated with Ni-NTA agarose beads (Invitrogen) with mild
rotation for 1.5 h at 4°C. After binding, the beads were washed three
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times with wash buffer (20 mM Tris–HCl [pH 7.4], 100 mM NaCl,
and 35 mM imidazole [pH 7.4]). Bead-bound proteins were eluted
with Laemmli buffer that contained either 50 mM DTT or 50 mM
IAA for reducing and non-reducing conditions, respectively. The
samples were denatured and subjected to SDS–PAGE and Western
blot.
UbiquitinHIS affinity purification
HEK293 cells were grown in low glucose for 24 h and co-transfected
with plasmids encoding ubiquitinHIS and COA7FLAG and grown in
galactose medium for 24 h in the presence of 1 mM MG132. The
cells were harvested and resuspended in denaturing lysis buffer
(6 M guanidine hydrochloride, 100 mM potassium phosphate buffer
[pH 8.0], 10 mM Tris–HCl [pH 8.0], 50 mM iodoacetamide, 20 mM
imidazole, 0.1% Triton X-100, 2 mM PMSF, and 1 mM MG132) for
15 min at room temperature. The cell debris was pelleted by
centrifugation for 15 min at 14,000 g at room temperature. The load
fractions were collected from the supernatant fraction. The remain-
ing supernatant was then incubated with Ni-NTA agarose beads
(Qiagen). The samples were incubated with Ni-NTA for 2 h at room
temperature with gentle mixing. After 2 h, the suspension was
subjected to centrifugation for 2 min at 200 × g and the supernatant
was discarded. Ni-NTA beads were washed once with lysis buffer
and three times with wash buffer (8 M urea, 100 mM KPi [pH 6.4],
and 10 mM Tris–HCl [pH 6.4], 30 mM imidazole). The protein
bound to Ni-NTA beads was eluted by resuspending in 2× Laemmli
buffer (4% SDS, 20% glycerol, 125 mM Tris–HCl [pH 6.8], and
0.02% bromophenol blue) containing 100 mM DTT at 65°C with
vigorous shaking. Load fraction was precipitated with 10% trichlor-
oacetic acid (TCA), washed with acetone, air-dried, and resus-
pended with 2× Laemmli buffer supplemented with 100 mM DTT.
All of the samples were denatured at 65°C and subjected to SDS–
PAGE and Western blotting.
Radioactive precursor synthesis and in organello import
The cDNA of precursors was cloned into a pTNT vector under the
SP6 promoter, and radiolabeled precursors were synthesized using
[35S]methionine and the TNT SP6 Quick Coupled Transcription/
Translation system (Promega). The precursors were precipitated by
ammonium sulfate and reduced in urea buffer (6 M urea and
60 mM MOPS-KOH [pH 7.2]) with 50 mM DTT. The import of radi-
olabeled precursors into isolated mitochondria was performed at
30°C in import buffer (250 mM sucrose, 80 mM potassium acetate,
5 mM magnesium acetate, 5 mM methionine, 10 mM sodium succi-
nate, 5 mM adenosine triphosphate, and 20 mM HEPES/KOH [pH
7.4]). Import was stopped by the addition of 50 mM IAA and incu-
bation on ice. Non-imported precursors were removed by proteinase
K treatment for 15 min. Proteinase K was then inactivated by the
addition of 2 mM PMSF, and mitochondria were washed with high-
sucrose buffer (500 mM sucrose and 20 mM HEPES/KOH [pH 7.4]).
The samples were solubilized in Laemmli sample buffer with
50 mM DTT and 0.2 mM PMSF and separated by SDS–PAGE and
autoradiography. The efficiency of protein import was quantified by
densitometry of the autoradiography images using the ImageQuant
TL program. The level of import into control mitochondria at the
indicated time point was set to 100%.
Redox state analysis of COA7
The oxidation state of COA7 was determined by direct and indirect
thiol trapping assays with isolated mitochondria. For the direct thiol
trapping assay, mitochondria were solubilized in Laemmli sample
buffer either with 50 mM DTT, or 10 mM IAA, or 15 mM AMS (Life
Technologies). For the indirect thiol trapping assay, mitochondria
were treated with IAA to block free cysteine residues for 10 min at
30°C. The solution was centrifuged at 20,000 g for 10 min at 4°C,
and mitochondria were resuspended in trehalose buffer that
contained 50 mM DTT at 65°C for 15 min to reduce the disulfide
bonds. Finally, mitochondria were solubilized in Laemmli buffer
with AMS for 30 min at 30°C. The samples were denatured and
analyzed by SDS–PAGE and Western blot.
Redox state analysis of MIA40— cells
HEK293 cells grown in galactose growth medium were harvested by
trypsinization, and proteins were precipitated by addition of
trichloroacetic acid (TCA, 9% final). As reference, control cells were
pretreated for 10 min at 37°C with 10 mM DTT or 10 mM diamide
to reduce or oxidize CPC motive of MIA40, respectively (Erdogan
et al, 2018). Precipitate was isolated by centrifugation, and the
pellet was washed with 5% TCA. The resulting pellet was solubi-
lized in urea buffer (6 M urea, 0.5% SDS, 10 mM EDTA, 200 mM
Tris–HCl [pH 7.5]) and aliquoted into samples reflecting approx.
1 × 106 cells. Samples were precipitated with ice-cold acetone (6:1
vol:vol) and stored at 20°C overnight. After thawing, the precipi-
tate was isolated by centrifugation, solubilized in 2× Laemmli
sample buffer supplemented with 1 mM PEG-PCMal, and incubated
at 37°C for 30 min. Sample was then mixed with 2× Laemmli
sample buffer supplemented with 100 mM DTT (1:1, vol:vol) and
denatured at 65°C for 20 min. Proteins were separated on SDS–
PAGE followed by Western blotting.
Redox state analysis of MIA40— mitochondria
Mitochondria isolated from HEK293 cells were resuspended in RIPA
supplemented with 1 mM PEG-PCMal. Mitochondria lysate was
incubated at 37°C for 30 min and centrifuged. The supernatant was
collected, mixed with 5× Laemmli sample buffer (2:1, vol:vol), and
denatured at 65°C for 20 min. As a control, mitochondria were solu-
bilized in RIPA buffer without PEG-PCMal and mixed 5× Laemmli
sample buffer with 50 mM DTT. Proteins were separated on SDS–
PAGE followed by Western blotting.
Proliferation in galactose assay
24 h prior to the experiment, human fibroblasts were seeded into
six-well format (two wells per experimental variant) at concentra-
tion of 0.1 × 106/well in the growth medium. At the day 0, cells
from two wells were detached by trypsinization and counted in a
cell counter (Countess II, Life Technologies). Medium in remaining
wells was exchanged into DMEM supplemented with 10 mM galac-
tose or 10 mM glucose, 10% (v/v) heat-inactivated fetal bovine
serum, 2 mM L-glutamine, 50 lg/ml uridine, 100 lM pyruvate,
100 U/ml penicillin, and 10 lg/ml streptomycin sulfate. After 24 h
of culture at 37°C with 5% CO2 (day 1), cells were harvested by
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trypsinization and counted. Cell growth was expressed as a fold
change of cell count on day 1 vs. day 0.
Complex IV activity
Approximately 10 × 106 immortalized fibroblast cells were cultured
for 24 h and subjected to proteasome inhibition. The cells were then
harvested by trypsinization and resuspended in buffer A (20 mM
MOPS/KOH [pH 7.4] and 250 mM sucrose) followed by digitonin
treatment (0.2 mg/ml) for 5 min at 4°C. The cell lysate was centri-
fuged at 5,000 g for 3 min. The supernatant that contained the
cytosolic fraction was discarded, and the pellet was resuspended in
buffer B (20 mM MOPS/KOH [pH 7.4], 250 mM sucrose, and 1 mM
EDTA). The solution was centrifuged at 10,000 g for 3 min, and the
pellet that contained permeabilized cells was resuspended in 10 mM
potassium phosphate buffer (pH 7.4) and frozen-thawed three times
in liquid nitrogen immediately before starting the spectrophotomet-
ric assay of complex IV activity (Tiranti et al, 1995). 200 ll of
100 lM reduced cytochrome c in 50 mM potassium phosphate
buffer (pH 7.0) was pipetted into 96-well format plate. The oxida-
tion of cytochrome c was initiated by addition of 10 ll of digitonized
cell suspension (10 ll potassium phosphate buffer for blank
sample), and the decrease in absorbance at 550 nm was recorded
for 3 min, which corresponded to linear changes in absorbance.
Specific activity of complex IV was calculated by subtracting the
absorbance change in the blank sample. The protein concentration
of digitonized cell suspension was measured by Bradford assay, and
complex IV activity was expressed in nanomoles of cytochrome c
per minute per milligram of protein.
Blue-Native PAGE— mitochondria
Isolated mitochondria were solubilized in digitonin buffer (1% [wt/
vol] digitonin, 20 mM Tris–HCl, pH 7.4, 50 mM NaCl, 10% [wt/vol]
glycerol, 0.1 mM EDTA, 1 mM PMSF) at the concentration of 1 lg
of mitochondria/ 1 ll buffer. The mitochondrial suspension was
resuspended by gentle pipetting and incubated at 4°C at 15 min.
After lysis, the cell suspension was centrifuged at 20,000 g for
15 min at 4°C. The supernatant was transferred to a prechilled
Eppendorf tube, and 10× loading dye was mixed by centrifuging at
20,000 g for 15 min at 4°C. The sample was directly applied to
4–13% gradient gel and resolved at 4°C. Protein complexes were
transferred to PVDF membranes and immunodecorated with specific
antibodies. The High Molecular Weight Calibration Kit for native
electrophoresis (Amersham) was used as a molecular weight
standard.
Blue-Native PAGE— digitonized cell lysate
Approximately 5 × 106 immortalized fibroblasts were harvested by
trypsinization and washed two times with ice-cold PBS. The cell
pellet was resuspended in 400 ll of cold 8 mg/ml digitonin suspen-
sion in PBS and incubated at 4°C for 15 min. Then, the lysate was
diluted with ice-cold PBS and centrifuged for 5 min at 10,000 g at
4°C. The pellet was resuspended in 200 ll of solubilization buffer
(1.5 M aminocaproic acid, 50 mM Bis-Tris–HCl pH 7.0) containing
20 ll of 10% DDM for 5 min at 4°C. After solubilization, samples
were centrifuged at 18,000 g for 30 min at 4°C. The supernatant
was mixed with 20 ll of sample buffer (750 mM aminocaproic acid,
50 mM Bis-Tris–HCl pH 7.0, 0.5 mM EDTA, and 5% Serva Blue G).
Samples were directly applied to 4–13% gradient gel and resolved at
4°C. Protein complexes were transferred to PVDF membranes and
immunodecorated with specific antibodies. The High Molecular
Weight Calibration Kit for native electrophoresis (Amersham) was
used as a molecular weight standard.
Immunofluorescence
HeLa cells or HeLa cells that stably expressed COA7-HA were trans-
fected with different subcompartment markers, namely matrix
targeted photoactivatable GFP (mtPAGFP) [matrix], COX8A-DsRed
[inner membrane], and TOMM20-DsRed [outer membrane], and
fixed with 3.7% formaldehyde after 24 h. The cells were permeabi-
lized (1% Triton X-100 and 0.1% sodium deoxycholate in phos-
phate-buffered saline [PBS]) and immunostained in blocking buffer
(5% goat serum and 0.1% IgG-free BSA in PBS) with anti-TOMM20
(Santa Cruz Biotechnology), anti-SMAC/DIABLO (Abcam), anti-
SDHA (Abcam), anti-Aconitase 2 (Abcam), anti-MDH2 (Atlas Anti-
bodies), anti-COA7 (Atlas Antibodies), or anti-HA (Cell Signaling
Technology) antibody and the respective secondary antibody (Alexa
Fluor 488 or 568, H+L- or IgG-specific, Invitrogen) and mounted
with Prolong Diamond (Invitrogen).
Super-resolution imaging and analysis
HeLa cells were transfected with different subcompartment markers
(mtPAGFP [matrix], COX8A-DsRed [inner membrane], and
TOMM20-DsRed [outer membrane]) and fixed with 3.7% formalde-
hyde after 24 h. The cells were permeabilized with 1% Triton X-100
and 0.1% sodium deoxycholate in PBS and immunostained in
blocking buffer (5% goat serum and 0.1% IgG-free BSA in PBS) with
anti-TOMM20 (Santa Cruz Biotechnology), anti-Smac/Diablo
(Abcam), anti-SDHA (Abcam), anti-Aconitase 2 (Abcam), anti-
MDH2 (Atlas Antibodies), and the respective secondary antibody
(Alexa Fluor 488 or 568, H+L- or IgG-specific, Invitrogen) and
mounted with Prolong Diamond. Acquisition was performed using
an N-SIM microscope system (Nikon) equipped with a super-resolu-
tion Apo TIRF 100× 1.49 NA objective and a DU897 Ixon camera
(Andor Technologies). Three-dimensional SIM image stacks were
acquired with a Z-distance of 0.15 lm. All of the raw images were
computationally reconstructed using the reconstruction slice system
from NIS-Elements software (Nikon) while keeping the same param-
eters. The co-localization analysis was performed using Imaris 9.0
XT software (Bitplane Scientific Software, St. Paul, MN, USA. For
each image, the threshold was applied in the same way as the
controls, and Pearson’s coefficient in the co-localized volume was
calculated for each image. The statistical analysis was performed
using GraphPad Prism software and one-way analysis of variance
(ANOVA) followed by Tukey’s multiple comparison post hoc test.
Mass spectrometry
The affinity-purified eluate fraction was resuspended in 100 ll of
100 mM ammonium bicarbonate buffer, reduced in 100 mM DTT
for 30 min at 57°C, alkylated in 55 mM iodoacetamide for 40 min at
RT in the dark, and digested overnight with 10 ng/ml trypsin (CAT
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NO V5280, Promega) at 37°C. Finally, to stop digestion trifluo-
roacetic acid was added at a final concentration of 0.1%. Mixture
was centrifuged at 4°C, 14,000 g for 20 min, to remove solid
remaining. MS analysis was performed by LC-MS in the Laboratory
of Mass Spectrometry (IBB PAS, Warsaw) using a nanoAcquity
UPLC system (Waters) coupled to a LTQ-Orbitrap Velos or Q Exac-
tive mass spectrometer (Thermo Fisher Scientific). The peptide
mixture were separated on precolumn (C18, Waters) coupled with
nano-HPLC RP18 column (Milford’s Waters, 75 lM) using 180 min
gradient (0–35% B) solution A: 0.1% TFA in water, B: CAN, 0.1%
TFA. The mass spectrometer was operated in the data-dependent
MS2 mode, and data were acquired in the m/z range of 300–2,000.
Peptides were separated by a 180 min linear gradient of 95% solu-
tion A (0.1% formic acid in water) to 35% solution B (acetonitrile
and 0.1% formic acid). The measurement of each sample was
preceded by three washing runs to avoid cross-contamination. Data
were analyzed with the MaxQuant (version 1.5.7.4) platform using
mode match between runs (Cox & Mann, 2008). The reference
human proteome database from UniProt was used (downloaded ta
2015.11.20). Variable modification was set for methionine oxida-
tion, acetyl at protein n-term, and fixed modification with carbami-
domethyl on cysteines. Label-free quantification (LFQ) intensity
values were calculated using the MaxLFQ algorithm (Cox et al,
2014). Identified proteins were analyzed as follows. Protein abun-
dance was defined as the signal LFQ intensity calculated by
MaxQuant software for a protein (sum of intensities of identified
peptides of given protein) divided by its molecular weight. Speci-
ficity (enrichment) was defined as the ratio of the protein LFQ inten-
sity measured in the bait purification (WT) to background (FP)
level. LFQ for proteins not detected was arbitrarily set to 1 for calcu-
lation reasons.
Molecular modeling
The structure of COA7 (UniProt id: Q96BR5) was modeled using the
Yasara Structure 17.1.28 package based on three Protein Data Bank
(PDB) structures (1OUV, 4BWR, and 1KLX) as templates (Luthy
et al, 2002, 2004; Urosev et al, 2013). These PDB structures were
selected automatically based on the combination of the blast E-
value, sequence coverage, and structure quality. For each template,
up to five alternate alignments with the target sequence were used,
and up to 50 different conformations were tested for each modeled
loop. The resulting models were evaluated according to structural
quality (dihedral distribution, backbone, and side-chain packing).
The model with the highest score of these that covered the largest
part of the target sequence was used as the template for a hybrid
model that was further iteratively improved with the best fragments
(e.g., loops) that were identified among the highly scored single-
template models.
Molecular dynamics
Molecular dynamics analysis was performed using the Yasara struc-
ture with a standard Yasara2 field (Krieger et al, 2009). The initial
structures were solvated in cubic boxes of water molecules, the
dimensions of which allowed at least 20 A˚ separation/distance
between the protein and box border. The general fold was initially
preserved by weak distance constraints that were applied for all
H-bonds that were identified in the helical regions. The molecular
dynamics simulations in the isothermal–isobaric ensemble (NPT)
were performed for an initial 5 ns with fixed backbone atoms (N,
Ca, and C) to enable optimization of the side chains. During the
next 25 ns, the system was released to evolve, and molecular
dynamics snapshots were taken every 10 ps.
The conformation and flexibility of all non-helical regions were
analyzed by the time evolution of phi and psi backbone angles, and
are presented as Ramachandran plots. All of these analyses were
performed with the R 3.3.0 package (www.r-project.org) using
custom-made scripts.
Statistics
All numerical data are expressed as a mean  SEM (standard error)
except of the quantification of immunofluorescence co-localization,
which is expressed as a mean  SD (standard deviation). The exact
P-values and the number of biological repeats (n) for each experi-
ment are indicated in the figure legends. If not stated otherwise, the
numerical data were a subject to the Shapiro–Wilk test for normal
distribution, and significance was calculated using the two-tailed
Student’s t-test. No randomization protocol was used. No blinding
protocol was used.
Expanded View for this article is available online.
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Problem
Mitochondrial diseases are a clinically heterogeneous group of genetic
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not treat the underlying pathological condition.
Results
The present study characterized a protein, COA7, previously shown to
be involved in the assembly and function of respiratory chain
complexes, as an intermembrane space protein and a new substrate
of MIA40. We also characterized pathogenic disease-causing COA7
variants and found that they were imported to mitochondria more
slowly than wild-type COA7. Consequently, both these mutant
proteins were mislocalized to the cytosol and degraded by the protea-
some. Proteasome inhibition resulted in an increased mitochondrial
localization of mutant proteins. Inhibition of the proteasome led to
an increase in the mitochondrial localization of mutant COA7 variants
and rescued mitochondrial levels of other affected mitochondrial
proteins. We also found that inhibition of the proteasome rescued a
defect of respiratory complex IV in COA7-deficient patient fibroblast.
Impact
The present study identified an important role for the proteasome in
degradation of mutant mitochondrial proteins under pathological
conditions. Inhibition of the proteasome may be beneficial for patients
who suffer from mitochondrial diseases that are characterized by a
lower amount of mitochondrial proteins. We raise the possibility that
proteasome inhibitors (e.g., bortezomib and carfilzomib) that are
already used clinically for cancer therapy can restore the levels of
mitochondrial proteins that despite being mutated conserve some
functionality when allowed to reach the right compartment. With
currently limited therapeutic options for treating mitochondrial
diseases, this strategy may be promising for the mitochondrial
diseases, in which mitochondrial protein depletion is observed and
contributes to lowering respiratory complex activity.
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